美国生物制药企业Metsera(MTSR.US)大涨超21.5%，报63.46美元。诺和诺德(NVO.US)跌近3%，报49.86美元。 消息面上，诺和诺德对Metsera发起一项收购要约，提出每股56.5美元的全现金报价，对应企业价值约60亿美元。辉瑞今年9月宣布，已同意以每股47.50美元现金收购Metsera，对应企业价值约49亿美元。若达到特定研发目标，辉瑞还将额外支付每股22.50美元，使得交易总价值达到73亿美元。(格隆汇)
美国生物制药企业Metsera(MTSR.US)大涨超21.5%，报63.46美元。诺和诺德(NVO.US)跌近3%，报49.86美元。 消息面上，诺和诺德对Metsera发起一项收购要约，提出每股56.5美元的全现金报价，对应企业价值约60亿美元。辉瑞今年9月宣布，已同意以每股47.50美元现金收购Metsera，对应企业价值约49亿美元。若达到特定研发目标，辉瑞还将额外支付每股22.50美元，使得交易总价值达到73亿美元。(格隆汇)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.